A Phase 2 interventional study of Oxaliplatin and s1 in Stomach Neoplasms, sponsored by Chinese Academy of Medical Sciences. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-04.
Sponsored by Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the efficacy and safety of oxaliplatin and s1 as first-line treatment of advanced gastric cancer.
There was no evidence of standard chemotherapy for advanced gastric cancer (AGC) in China. Fluoropyrimidines and cisplatin have been widely used in a variety of combinations in the treatment of AGC. Capecitabine/cisplatin combination therapy showed an overall response rate (ORR) of 41- 55%, a median time to progression/progression free survival (TTP/PFS) of 5.6-6.3 months, and a median overall survival (OS) of 10.1-10.5 months. Though no studies have compared two oral fluoropyrimidines in combination with oxaliplatin, both S-1 and capecitabine appear to be comparable in terms of efficacy and safety. The investigators conducted a phase II trial of oxaliplatin combined with S-1 in the treatment of first-line AGC.
2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.
This study's enrollment of 43 is below the median of 67 across 2,096 interventional studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Chinese Academy of Medical Sciences is the lead sponsor of 235 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
oxaliplatin+s1
Drug: Oxaliplatin · Drug: s1
130mg/m2 d1,repeated q21d
Also known as: eloxatin
80mg/m2/d, d1-14,repeated q21d
Also known as: TS-1
Progression Free Survival
from date of treatment was administered until the date of first documented progression or death from any cause whichever first, assessed every 6 weeks
Time frame: 2 years
Response Rate
From date of treatment was administered until the date of first documented response to treatment according to RECIST criteria,assessed every 2 cycles
Time frame: 2 years
overall survival
From date of treatment was administered until the date of death from any cause,assessed every 3 months
Time frame: 2 years
number of participants with adverse events
assessed from treatment was administered until 1 months after withdrawing from study
Time frame: 2 years
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences